Outcome of the board meeting held on 29th May 2025 for approval of Audited financial statements for Quarter and year ended on March 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Omkar Pharmachem Ltd approved audited financial results for Q4 and full year ended March 31, 2025. The company reported zero revenue from core operations (Net Sales/Income from Operations = Rs. 0.00), with only 'Other Operating Income' of Rs. 54.00 lakh for FY25, unchanged from the previous year. Profit Before Tax rose modestly to Rs. 27.00 lakh (from Rs. 25.28 lakh), and Profit After Tax grew to Rs. 20.09 lakh (from Rs. 18.91 lakh), translating to EPS of Rs. 0.1992 vs Rs. 0.1875. Operating cash flow remained positive at Rs. 24.35 lakh, short-term borrowings were cut sharply from Rs. 30.31 lakh to Rs. 11.85 lakh, and cash balance improved to Rs. 10.94 lakh. The statutory auditor (Dipal R. Shah & Co.) issued an unmodified/clean opinion. Additionally, M/s. Maulik Bhavsar and Associates was appointed as Secretarial Auditor for a 5-year term.
For shareholders: the company is essentially dormant with no real operating revenue, relying only on other operating income, and carries negative reserves of Rs. 65 lakh — limited near-term growth visibility. However, shrinking debt, positive cash flow, and improving reserves offer some stability. This is unlikely to be a significant catalyst for the stock price.